Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 18/20 | 0.45 |
| ▸ | FLT4 | P35916 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524833 | 0.92 | PTK2 (0.44) | PTK2FLT4 | |
| SCHEMBL15524484 | 0.92 | PTK2 (0.43) | PTK2FLT4 | |
| SCHEMBL15524248 | 0.91 | PTK2 (0.41) | PTK2FLT4CSF1RCDK4CDK6 | |
| SCHEMBL12478260 | 0.89 | PTK2 (0.54) | PTK2FLT4 | |
| SCHEMBL15524349 | 0.87 | FLT4 (0.52) | PTK2FLT4 | |
| SCHEMBL15524531 | 0.86 | PTK2 (0.49) | PTK2FLT4 | |
| SCHEMBL12479026 | 0.86 | PTK2 (0.51) | PTK2FLT4 | |
| SCHEMBL12478593 | 0.85 | PTK2 (0.55) | PTK2FLT4 | |
| SCHEMBL15524434 | 0.85 | PTK2 (0.49) | PTK2FLT4 | |
| SCHEMBL15524388 | 0.85 | PTK2 (0.42) | PTK2FLT4CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20080152911-A1 | TEMPLATED METAL PARTICLES AND METHODS OF MAKING | 3M INNOVATIVE PROPERTIES COMPANY | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | PTK2 240/4885FLT4 1/4885CSF1R 118/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | PTK2 260/4885FLT4 1/4885CSF1R 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.